Minerva Neurosciences reported $65.59M in Cash and Equivalent for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 94.64M 172.32M
Adma Biologics ADMA:US $ 34.41M 8M
ALKERMES ALKS:US $ 310.44M 52.1M
Arena Pharmaceuticals ARNA:US $ 386.65M 127.52M
AstraZeneca AZN:LN 7067M 8500M
Biocryst Pharmaceuticals BCRX:US $ 199.6M 10.72M
Bristol Myers Squibb BMY:US $ 13540M 2516M
Dynavax Technologies DVAX:US $ 246.35M 116.74M
Eli Lilly And LLY:US $ 3788.2M 568.2M
Esperion Therapeutics ESPR:US $ 103.67M 115.51M
GlaxoSmithKline GSK:LN 3453M 50M
Halozyme Therapeutics HALO:US $ 491.68M 44.72M
Kindred Biosciences KIN:US $ 46.72M 33.8M
Marinus Pharmaceuticals MRNS:US $ 145.1M 32.61M
Minerva Neurosciences NERV:US $ 65.59M 8.63M
Neurocrine Biosciences NBIX:US $ 311.1M 56.9M
Novartis NOVN:VX SF 7211M 2094M
Novavax NVAX:US $ 366.24M 128.21M
Takeda 4502:JP Y 607881M 47039M
Vanda Pharmaceuticals VNDA:US $ 50.52M 6.72M